Audrey Romero, MD
Obstetrics & Gynecology · West Orange, NJNPI 1942235692
Payments from drug & device makers
Across 254 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celularity Inc.$2K
- Astellas Pharma US Inc$722
- Sumitomo Pharma America, Inc.$476
- AbbVie$412
- Mayne Pharma Commercial LLC$296
- Agile Therapeutics, Inc.$183
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$2,10036%
- Food & beverage$3,46859%
- Education$2975%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Celularity Inc. | 9 | $2,124 |
| Astellas Pharma US Inc | 26 | $722 |
| Sumitomo Pharma America, Inc. | 52 | $476 |
| AbbVie(2 entities) | 34 | $412 |
| Mayne Pharma Commercial LLC | 22 | $296 |
| Agile Therapeutics, Inc. | 12 | $183 |
| Pfizer | 9 | $145 |
| Evofem Biosciences, Inc. | 10 | $145 |
| Millicent US Inc | 7 | $121 |
| Exeltis, USA Inc. | 8 | $121 |
| Coopersurgical, Inc. | 7 | $85 |
| Therapeuticsmd, Inc. | 5 | $83 |
| Merck | 5 | $75 |
| Bayer | 3 | $70 |
| Avion Pharmaceuticals | 5 | $66 |
| Hologic Sales And Service, LLC | 3 | $62 |
| Axonics, Inc. | 3 | $62 |
| Amgen | 4 | $55 |
| Medtronic | 1 | $54 |
| Myovant Sciences Inc. | 3 | $44 |
| Urovant Sciences Inc | 3 | $42 |
| Sage Therapeutics, LLC | 2 | $36 |
| Baxter Healthcare | 1 | $35 |
| Dentsply IH Inc. | 1 | $33 |
| LSI Solutions Inc | 1 | $32 |
| AMAG Pharmaceuticals, Inc. | 2 | $32 |
| Organon | 2 | $27 |
| Medicem Inc. | 1 | $26 |
| Exact Sciences | 1 | $26 |
| Lupin Inc. | 2 | $25 |
| Femselect Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Dysis Medical, Inc. | 1 | $13 |
| Duchesnay USA Incorporated | 1 | $12 |
| Scynexis, Inc. | 1 | $12 |
How this compares
$5,865 in reported general payments places this provider in the 90th percentile of 1,242 obstetrics & gynecology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 39 | $44,064 |
| GemtesaVibegron | 41 | $31,517 |
| Estradiol | 152 | $13,266 |
| PremarinEstrogens, Conjugated | 26 | $12,074 |
| PremproEstrogen,con/M-Progest Acet | 11 | $7,552 |
| IntrarosaPrasterone (Dhea) | 12 | $4,487 |
| Estradiol (Twice Weekly)Estradiol | 19 | $1,012 |
| Metronidazole | 19 | $745 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $585 |
| Clobetasol Propionate | 19 | $377 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $295 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 34 | $277 |
| ValacyclovirValacyclovir Hcl | 11 | $268 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $105 |
| Alendronate Sodium | 12 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $722 | $44,06439 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $476 | $31,51741 claims |
| PfizerPremarin, Prempro | $145 | $19,62637 claims |
| AMAG Pharmaceuticals, Inc.Intrarosa | $32 | $4,48712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,242 obstetrics & gynecology providers in New Jersey.
Other obstetrics & gynecology in West Orange
- Susan PitmanWest Orange$77K
- Robert RubinoWest Orange$42K
- Jennifer AshtonEnglewood$1.5M
- Gregory HirschMorristown$1.3M
- Steven SussmanLawrenceville$623K
- Geoffrey BowersVoorhees$228K
- Neha DeshpandePlainsboro$206K
- Justin ChuraSwedesboro$193K
- Paula JasionowskiVoorhees$193K
- Peter ChenSewell$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.